White paper

GLP-1 anti-obesity medications: A new frontier in the fight against obesity

  • Friedman_Michelle

    Michelle Friedman

  • headshot

    Shaila Yoshida

Explore the evolving landscape of anti-obesity medications (AOMs) in this comprehensive white paper, focused on GLP-1 receptor agonists: a powerful class of treatments revolutionizing obesity care. From the clinical efficacy of FDA-approved medications like Wegovy® and Zepbound® to payer coverage challenges, regulatory updates, and future market projections, this resource provides critical insights for healthcare decision-makers, payers, providers, and policy advocates. Learn how AOMs are addressing unmet needs in obesity treatment, the economic impacts of obesity on healthcare systems, and strategies to optimize access and outcomes.

Key highlights:

  • Trends in the prevalence and treatment of obesity
  • Historical milestones in AOM development
  • Challenges in payer coverage, supply chain, and patient adherence
  • Future outlook for innovation, regulatory policy, and market growth

Discover how GLP-1 AOMs are shaping the future of obesity management and transforming patient health outcomes. Access the white paper now to stay ahead in the dynamic AOM market.
AOM WP pdf preview

Access the white paper

Pardot Form

Connect with our team

Our commitment to helping clients achieve market access plays a crucial role in patients’ access to affordable, diverse, and effective therapies so they can achieve their best potential health outcomes. Connect with our team of experts to discover how we can help support your goals.

Related resources

Business meeting with 4 participants.

Report

FDA programs on the horizon: What biopharma companies need to know
Learn more
'"

Guide

Five strategic shifts to lead pharma through change
Learn more
HTA Quarterly

Article

HTA Quarterly Fall 2025 Summary
Learn more

Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.

Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.